Padcev

Pharma

Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears

With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s BD strategy ahead of the loss.

Angus Liu Jan 15, 2026 10:42am

An arrow incrementally going up stairs before pointing straight up Blue background

Keytruda, Padcev keep winning streak in bladder cancer

Dec 17, 2025 9:53am

FDA safety probe, Otsuka, ADC patent fight—Fierce Pharma Asia

Dec 5, 2025 8:45am

Padcev, Keytruda combo scores game-changing FDA nod

Nov 21, 2025 1:22pm

On target clinical trial success bullseye score

Keytruda, Padcev cut risk of death by 50% in MIBC patient subset

Oct 18, 2025 10:30am

Roche touts Tecentriq biomarker win in bladder cancer

Aug 18, 2025 4:17pm